KDR and adrenal cortex carcinoma: Studies on Sunitinib, which targets VEGFR and PDGFR, indicated limited efficacy, with a PFS of less than 3 months in patients with refractory ACC, partially due to drug interactions with mitotane, which decreases TKI blood levels (49).